The study design is a 4 - week parallel-arm intervention, randomised controlled trial.
Participants will attend 2 testing days, baseline and follow-up 4 weeks apart.

Participants will first be screened over the phone to assess eligibility. Participants
will then be randomly allocated using minimisation, into either control or intervention
arm.

Baseline testing:

Participants will undergo baseline testing in the laboratory.

Participants will be measured for their anthropometrics; height and weight. Participants
will complete a series of questionnaires for 15 mins.

Following 15 minutes rest, participants will then have three resting blood pressure and
heart rate measurements and averaged via a sphygmomanometer and polar HR watch.

MIP will be measured using the MicroRPM care fusion 3 times and the highest value
reported (10 minutes). Forced expiratory value in 1 second (FEV1) and peak expiratory
flow (PEF) will be measured using Vitalograph 700 (Spirotrac 6).

Participants will undergo a 6-minute-walk-test self-paced where Rating of perceived
exertion (RPE) and Borg dyspnea scale (BDS) will be assessed each minute. Then a
sub-maximal exercise test using a cycle ergometer and VyntusCPX, where Ventilatory
threshold (VT) and Maximal heart rate (HRMax)will be measured. Participants will be asked
to cycle until they reach a 17 RPE on a ramp test of 10-15W/min (>20mins). Heart rate
(HR), Rating percieved exertion (RPE) and Borg dyspnea scale BDS) measured each minute.

The intervention arm will receive a handheld PrO2 device and will participate in two
unsupervised sessions and one supervised via Microsoft teams sessions per week.
Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6
x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day. The
control group will be asked to continue as normal throughout the 4 weeks.